(Image: NDTV Profit) Show Quick Read Summary is AI Generated. Newsroom Reviewed

Biocon is stepping into a decisive new phase in its evolution as a global biosimilars powerhouse, propelled by regulatory shifts in the US, fresh strategic partnerships, and a strengthened insulin and GLP-1 pipeline, executive chairperson Kiran Mazumdar-Shaw told The Economic Times.

She said the company is now uniquely positioned to accelerate growth, lighten its financial load, and scale deeper into the high-value biologics market.

“We are in a sweet spot and a very unique position,” Mazumdar-Shaw said in her conversation with ET. She pointed out that Biocon is the only player with interchangeable insulins at a time when traditional insulin manufacturers are shifting their focus toward GLP-1s. “We are

See Full Page